drugset / Trial / NCT06317298
Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will assess the efficacy and safety profile of fruquintinib in combination with everolimus as second line therapy of clear cell renal cell carcinoma patients who progressed after immunotherapy and tyrosine kinase inhibitor.
Timeline
- Start
- 2024-02-21
- Primary completion
- 2025-08-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | — |
| Subject | Fruquintinib | Small molecule | 3 mg | — |
| Subject | Fruquintinib | Small molecule | 4 mg | — |
| Subject | Fruquintinib | Small molecule | 5 mg | — |